Xlife Sciences AGXSWX:XLS -11.06%50 EBITDA Margin % is 3,920.25% as of Dec. 2025, which is 85% above its 10-year median of 2,120.34. GuruFocus rates XSWX:XLS with a GF Score™ of 50/100 and a GF Value™ of CHF7.30 (Significantly Overvalued). The stock has 13 warning signs investors should review. Among 945 Biotechnology companies, Xlife Sciences AG ranks worse than 80.21% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Xlife Sciences AG's EBITDA for the
six
months ended in Dec. 2025 was CHF-3.10 Mil. Xlife Sciences AG's Revenue for the
six
months ended in Dec. 2025 was CHF-0.08 Mil. Therefore, Xlife Sciences AG's EBITDA margin for the quarter that ended in Dec. 2025 was 3,920.25%.
Xlife Sciences AG (XSWX:XLS) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Xlife Sciences AG EBITDA Margin % Related Terms
Xlife Sciences AG EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Xlife Sciences AG's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:XLS vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Xlife Sciences AG's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xlife Sciences AG EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xlife Sciences AG's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Xlife Sciences AG's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xlife Sciences AG (XSWX:XLS) has a EBITDA Margin % of 3,920.25% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Xlife Sciences AG and its competitors. This is 85% above median its historical median of 2,120.34. According to the industry distribution chart, Xlife Sciences AG ranks #758 out of 945 companies in the Biotechnology industry, placing it in the top 80.2%.
Is Xlife Sciences AG's EBITDA Margin % too high?
Xlife Sciences AG's current EBITDA Margin % of 3,920.25% is 85% above median its 10-year median of 2,120.34. Based on the distribution chart, Xlife Sciences AG ranks #758 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Xlife Sciences AG has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xlife Sciences AG's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Xlife Sciences AG ranks #758 out of 945 companies for EBITDA Margin %. This places Xlife Sciences AG in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Xlife Sciences AG and its competitors. Xlife Sciences AG's current EBITDA Margin % is 3,920.25%, which is 85% above median its own 10-year median of 2,120.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xlife Sciences AG stock overvalued right now?
Based on GuruFocus' analysis, Xlife Sciences AG (XSWX:XLS) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF7.30, compared to a current price of CHF20.90 — trading 186.3% above its estimated fair value. The current EBITDA Margin % is 3,920.25%, which is 85% above median its 10-year median of 2,120.34. Xlife Sciences AG's overall GF Score™ is 50/100 with 13 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Xlife Sciences AG (XSWX:XLS), the current EBITDA Margin % is 3,920.25% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xlife Sciences AG (XSWX:XLS) Overvalued in 2026?
Based on GuruFocus' analysis, Xlife Sciences AG stock appears to be overvalued.
The current stock price of CHF20.90 is trading 186.3% above its estimated GF Value™ of CHF7.30.
GuruFocus considers Xlife Sciences AG to be Significantly Overvalued.
Key valuation signals for XSWX:XLS:
EBITDA Margin %: 3,920.25% (85% above median its 10-year median of 2,120.34)
GF Value™: CHF7.30 vs. price of CHF20.90 (186.3% above fair value)
No single metric tells the full story. See the XSWX:XLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xlife Sciences AG is a Swiss incubator and accelerator company focused on the value development and commercialization of research projects from universities and other life science research institutions, to provide solutions for high-unmet medical needs. It holds majority or minority interests in project companies that are engaged in areas of the company's reportable segments, which include Technology platforms, Medical Technology, Biotechnology/Therapeutics, and Artificial Intelligence/Digital Medicine.
50GF Score
Get the complete analysis for XSWX:XLS
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:XLS has been successfully added to your 
